Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Veru Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for oncology and women’s health. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on hormone-driven cancers and reproductive health conditions. Veru’s strategy centers on leveraging proprietary drug delivery technologies and repurposing or reformulating known active pharmaceutical ingredients to address unmet medical needs.
The company’s primary revenue drivers historically came from its Sexual Health Products business, particularly the FC2 Female Condom, while its current strategic focus is on late-stage and early-stage drug development in oncology. Veru was originally founded in 1996 as The Female Health Company and later rebranded as Veru Inc. in 2017 to reflect its broader pharmaceutical ambitions, including oncology drug development and therapeutic innovation beyond medical devices.
Business Operations
Veru operates through two main business segments: Biopharmaceutical Development and Sexual Health Products. The biopharmaceutical segment focuses on developing drug candidates such as enobosarm, a selective androgen receptor modulator (SARM), and sabizabulin, a microtubule disruptor investigated in oncology indications. This segment does not yet generate significant recurring revenue and is primarily funded through capital markets and strategic resource allocation.
The Sexual Health Products segment includes the manufacturing and global distribution of the FC2 Female Condom, which has been sold to public health organizations, nongovernmental organizations, and government agencies worldwide. Operations include regulatory approvals, manufacturing oversight through third-party manufacturers, and international procurement contracts, particularly in public health markets. Veru does not operate large-scale manufacturing facilities directly and relies on external partners for production.
Strategic Position & Investments
Veru’s strategic direction prioritizes advancing its oncology pipeline through clinical development, regulatory engagement, and potential commercialization or partnership opportunities. The company has invested heavily in clinical trials for enobosarm in breast cancer and sabizabulin in prostate and other cancers, reflecting a shift toward higher-value therapeutic areas with significant unmet needs.
The company has also restructured its portfolio over time, including divestitures and reduced emphasis on non-core assets to concentrate capital on oncology. Veru’s subsidiaries include The Female Health Company (UK) plc, which supports international sexual health operations. Data on additional material acquisitions or equity investments is limited, and some disclosures regarding long-term pipeline commercialization timelines remain inconclusive based on available public sources.
Geographic Footprint
Veru is headquartered in Miami, Florida, United States, and maintains a global operational footprint through international sales and distribution of its sexual health products. The company’s pharmaceutical research and development activities are primarily coordinated in the United States, with clinical trials conducted across multiple regions depending on study design.
The FC2 Female Condom has been distributed in Africa, Asia, Latin America, Europe, and North America, primarily through public health programs supported by international aid organizations. While Veru does not maintain extensive physical infrastructure abroad, its international influence is driven by regulatory approvals, tender-based procurement, and partnerships with global health agencies.
Leadership & Governance
Veru’s leadership emphasizes disciplined capital allocation, focus on late-stage clinical assets, and targeting large, well-defined patient populations. The company is publicly traded and governed by a board of directors responsible for oversight of strategy, risk management, and regulatory compliance.
Key executives include:
- Mitchell S. Steiner – Chief Executive Officer
- Harry Fisch – President
- Muhammad Abdul Hayee – Chief Financial Officer
- Zhiwei He – Chief Science Officer
- Steven A. Bigelow – Chief Medical Officer
The leadership team’s strategic vision centers on transitioning Veru from a mixed device-and-drug company into a focused oncology biopharmaceutical company while maintaining selective cash-generating sexual health operations to support long-term development goals.